miR-509-3p alteration of YAP1/ECM axis (WP3967)
Homo sapiens
Summary of findings for miR-509-3p and the YAP1/ECM axis. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041955/ Collectively, the results suggest that miR-509-3p-mediated changes in levels of YAP1 and ECM genes impair migration, invasion, and spheroid formation and so may attenuate metastatic progression in advanced stage ovarian cancer. Further, results suggest that the direct downstream miR-509-3p target YAP1 is likely a critical driver of cellular migration and spheroid formation in ovarian cancers in which levels of YAP1 protein are high. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP3967 CPTAC Assay Portal].
Authors
Kristina Hanspers and Friederike EhrhartActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
- Disrupting biological sensors of force promotes tissue regeneration in large organisms (2021).
- Heterogeneity of Lipid and Protein Cartilage Profiles Associated with Human Osteoarthritis with or without Type 2 Diabetes Mellitus (2021).
- Predictive models for stage and risk classification in head and neck squamous cell carcinoma (HNSCC) (2020).
- Phenotypic and functional characterization of corneal endothelial cells during in vitro expansion (2020).
- Interactive neuroinflammation pathways and transcriptomics-based identification of drugs and chemical compounds for schizophrenia (2023).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
ExRNAAnnotations
Disease Ontology
ovarian cancer cancerPathway Ontology
Hippo signaling pathway cancer pathway| Label | Type | Compact URI | Comment |
|---|---|---|---|
| BCAR1 | GeneProduct | ensembl:ENSG00000050820 | |
| EDNRA | GeneProduct | ensembl:ENSG00000151617 | |
| FN1 | GeneProduct | ensembl:ENSG00000115414 | |
| SPARC | GeneProduct | ensembl:ENSG00000113140 | |
| THBS2 | GeneProduct | ensembl:ENSG00000186340 | |
| GPC6 | GeneProduct | ensembl:ENSG00000183098 | |
| COL1A1 | GeneProduct | ensembl:ENSG00000108821 | |
| COL3A1 | GeneProduct | ensembl:ENSG00000168542 | |
| COL5A1 | GeneProduct | ensembl:ENSG00000130635 | |
| PBX3 | GeneProduct | ensembl:ENSG00000167081 | |
| TWIST1 | GeneProduct | ensembl:ENSG00000122691 | |
| SNAI2 | GeneProduct | ensembl:ENSG00000019549 | |
| YAP1 | GeneProduct | ensembl:ENSG00000137693 | |
| MIR509-3 | GeneProduct | hgnc.symbol:MIR509-3 | |
| TEAD1 | GeneProduct | ensembl:ENSG00000187079 | |
| TEAD2 | GeneProduct | ensembl:ENSG00000074219 | |
| TEAD3 | GeneProduct | ensembl:ENSG00000007866 | |
| TEAD4 | GeneProduct | ensembl:ENSG00000197905 |
References
- miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, et al. Oncotarget. 2016 May 3;7(18):25930–48. PubMed Europe PMC Scholia